丝甘蛋白聚糖在乳腺癌对多柔比星耐药过程中的重要性研究

发布时间：2018-03-26 22:07

  本文选题：乳腺癌　切入点：多柔比星　出处：《中国药学杂志》2017年04期

【摘要】：目的研究丝甘蛋白聚糖(serglycin)的表达高低是否会影响乳腺癌细胞系对多柔比星的敏感性。方法用瞬时干扰的方法敲低丝甘蛋白聚糖在MDA-MB-231中的表达水平,且用qRT-PCR,免疫荧光的方法验证敲低效率;用MTS法测定多柔比星在阴性对照(NC)组和Si-丝甘蛋白聚糖(Si-SG)组中的IC_(50)值,以及测定在0.018μmol·L-1多柔比星的作用下两组的增殖曲线;用克隆形成的方法观察在不同药物压力下两组克隆形成数的差异。结果瞬时干扰的效率达到70%以上;MTS方法检测Si-SG组的IC_(50)值以及药物压力下的增殖曲线均显著低于NC组;且在不同药物压力下的克隆形成能力也显著低于NC组。结论在MDA-MB-231中瞬时干扰丝甘蛋白聚糖能够显著增强MDA-MB-231对多柔比星的敏感性。
[Abstract]:Objective to study whether the expression level of serglycinin affects the sensitivity of breast cancer cell line to doxorubicin. The knock efficiency was verified by qRT-PCR and immunofluorescence, the ICS-50 value of doxorubicin in negative control group and Si-seroglycan group was determined by MTS method, and the proliferation curve of the two groups under the action of 0.018 渭 mol L-1 doxorubicin was determined. Results the instantaneous interference efficiency was more than 70% in Si-SG group and the proliferation curve under drug pressure was significantly lower than that in NC group. The clone formation ability under different drug pressure was also significantly lower than that in NC group. Conclusion transient interference silk glycosaminoglycan in MDA-MB-231 can significantly enhance the sensitivity of MDA-MB-231 to doxorubicin.
【作者单位】： 中山大学附属肿瘤医院华南肿瘤学国家重点实验室;
【基金】：国家自然科学基金青年科学基金(81302317) 广东省科技计划项目(2014B020212017,2014A020209024)
【分类号】：R737.9
，

本文编号：1669789